Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06349798
Other study ID # DR200177
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date April 2024
Est. completion date April 2027

Study information

Verified date April 2024
Source University Hospital, Tours
Contact Francis REMERAND, MD PhD
Phone 02.47.47.85.51
Email f.remerand@chu-tours.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NEFARTHRO is a multicentric randomized controlled trial comparing the effects of discontinuous infusions of nefopam (bolus) versus continuous infusion of intravenous nefopam (via an infusion pump) versus placebo on the opioid-request during the first 24 hours following a Total Hip arthroplasty, as part of multimodal analgesia including at least paracetamol and a Non-Steroidal Anti-Inflammatory Drug (NSAID). The primary endpoint is cumulative morphine consumption for the first postoperative 24 hours, expressed in mg of iv equivalent morphine, including titration in the Post Anesthesia Care Unit (PACU). Patients will be followed during 6 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 546
Est. completion date April 2027
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patient aged = 18 years, fluent in French. - Planned primary or secondary total hip replacement, regardless of surgical approach or type of prosthesis. - Receiving paracetamol and ketoprofen postoperatively. - Under general anesthesia or spinal anesthesia (without intrathecal morphine). - Participant affiliated to a social security scheme - Participant's free, informed and written consent Exclusion Criteria: - Septic or carcinological surgery - Allergy to paracetamol, nefopam or NSAIDs - Angle-closure glaucoma - Prostate adenoma - history of convulsion - Nocturnal pollakiuria in men with more than two risings per night - Severe hepatic (Child C) or cardiac insufficiency (LVEF < 30%) - Renal insufficiency with creatinine clearance < 50 mL/ min according to Cockroft's formula - Active peptic ulcer or history of digestive bleeding or peptic perforation - Patients with opioid treatment for chronic pain other than coxarthrosis (fentanyl, oral morphine > 50mg/d or equivalent) - Protected patient: safeguard of justice, guardianship or curatorship - Incomprehension or inability to use a numerical rating scale or to self-assess/manage pain - Pregnancy or breast-feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nefopam
20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
Nefopam
20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
NaCl 0.9%
50 ml of saline, during a 30 min infusion, before end of procedure, followed by a bolus of placebo every 4 hours for 24 hours (6 injections in all) + continuous infusion of placebo (2 mL/h of physiological saline)

Locations

Country Name City State
France Anaesthesia - Intensive care Angers
France Anaesthesia - Intensive care Blois
France Anaesthesia - Intensive care Chartres
France Anaesthesia - Intensive care Nantes
France Anaesthesia - Intensive care Orléans
France Anaesthesia - Intensive care Poitiers
France Anesthesia - intensive care Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative morphine consumption from the end of surgery (Day 0 - Hour 0) to the first 24 hours after surgery, expressed in mg of intravenous morphine (including titration in the Post-Anesthesia care Unit PACU). between Day 0 - Hour 0 and Hour 24 post surgery
Secondary Maximum self-assessed pain using the Numeric Rating Scale ranging from 0 (no pain) to 10 (maximum pain) at rest in the PACU, at rest and on walking between PACU discharge and Hour 24, at Hour 24, and at hospital discharge. at PACU, between PACU discharge and Hour 24, at Hour 24 and at Day 5 of hospital discharge
Secondary Time to return to walking. At Hour 24, at Day 5 or at discharge, whichever came first and at Month 6
Secondary Time to leave room. At Hour 24, at Day 5 or at discharge, whichever came first and at Month 6
Secondary Time to climb stairs. At Hour 24, at Day 5 or at discharge, whichever came first and at Month 6
Secondary Length of stay. At Day 0 - Hour 0 up to Day 5 or at discharge
Secondary Time to abandon canes/crutches. At Hour 24, at Day 5 or at discharge, whichever came first and at Month 6
Secondary Opioid analgesic consumption between days 1 and 5 or at hospital discharge at Hour 24 and up to day 5
Secondary Chronic pain at 6 months (at rest and walking) using a standardized phone questionnaire. At Month 6
Secondary Neuropathic pain score (DN2)The DN2 is a simplified version of the DN4, with 7 items: burning, painful cold, electric shocks, tingling, pins and needles, numbness, itching (scored 0=absent, 1=present). At Hour 24 and Month 6
Secondary Incidence of all serious AEs during patient follow-up and non-serious AEs. at Hour 24 and up to day 5
Secondary Incidence of patients with morphine side effects Incidence of patients with morphine side effects: nausea, vomiting, use of anti-nausea medication, pruritus requiring modification of management, urinary retention, use of urinary antispasmodics or urethral catheterization/suprapubic catheter, or abnormal drowsiness. at Hour 24 and up to day 5
Secondary Financial impact of spreading the recommended strategy following the results of the clinical study, estimated per year and over a 5-year period, from the point of view of the French Health Insurance and from the hospital perspective. These financial impacts will be estimated using budget impact models. 5 years
See also
  Status Clinical Trial Phase
Terminated NCT02818894 - Spinal Anesthesia in Total Hip Arthroplasty Phase 4
Completed NCT02242201 - Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular Phase 4
Completed NCT02414542 - Minima Clinical Study
Completed NCT01817010 - Strength and Function Following Total Hip Arthroplasty N/A
Completed NCT01443975 - Clinical Evaluation on the Use of the X-pander Device N/A
Recruiting NCT05530551 - Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA N/A
Recruiting NCT05530174 - Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture N/A
Recruiting NCT06141928 - Comparison of Three Different Surgical Approaches on the Functional Outcome After Total Hip Arthroplasty N/A
Recruiting NCT05054192 - Reliability and Validity of Modified Four Square Step Test
Recruiting NCT04492462 - The Impact of Two Different Physical Therapy Programs in the Rehabilitation of Patients Undergoing Anterior Approach Hip Replacement Surgery N/A
Withdrawn NCT02926651 - Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty Phase 4
Completed NCT02308813 - Predictability of the Ability to Perform an Emergency Stop With Disorders of the Hip N/A
Recruiting NCT02032017 - Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation. N/A
Recruiting NCT01312077 - The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement Phase 4
Withdrawn NCT01380665 - Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty Phase 4
Recruiting NCT05893563 - Corail Stability at 5-Years Post-Total Hip Arthroplasty
Recruiting NCT06088069 - Effect of Virtual Reality on Perioperative Anxiety, Stress and Pain in Total Hip Arthroplasty N/A
Active, not recruiting NCT03210844 - The Clinical Outcomes After Direct Anterior Approach and Microposterior Approach for Total Hip Arthroplasty N/A
Recruiting NCT04801680 - Mpact 3D Metal Cup PMS
Terminated NCT02006251 - Real-Time Instrument for Acetabular Shell Positioning